Consensus Alector, Inc.

Stocks

ALEC

US0144421072

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2026-09-24 pm EDT			5-day change	1st Jan Change
1.920 ^USD	-4.95%		+3.78%	+23.08%

Sep. 16	Novartis halts ALS drug development after mid-stage trial failure	RE
Sep. 15	Alector, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 07:00 AM

Evolution of the Average Target: Alector, Inc.

Evolution of the Target Price: Alector, Inc.

Changes in Analyst Recommendations: Alector, Inc.

016e30b8262856519d10a7d8de.GWoYVgLz9tmu7x-yha8TWBzXDEdPdRgkUBfL75ltZcY.dwtfBkGsor_ooiaL_8pRFW6YYnEqDGJqPyb4o84PA6JcOSkRML-x75ihXg~d2de3ce780b853a79942c8788a925a67

Analysts' recommendations: Alector, Inc.

Apr. 15	Alector Shares Rise After Cantor Fitzgerald Upgrade	MT
Apr. 15	Cantor Fitzgerald Upgrades Alector to Overweight From Neutral	MT
Mar. 10	Alector Shares Rise After BTIG Upgrade	MT
Mar. 10	BTIG Upgrades Alector to Buy From Neutral, Price Target is $6	MT
25-10-22	Top Midday Decliners	MT
25-10-22	William Blair Downgrades Alector to Market Perform From Outperform	MT
25-10-22	TD Cowen Downgrades Alector to Hold From Buy	MT
25-10-22	BTIG Downgrades Alector to Neutral From Buy	MT
25-10-22	Cantor Fitzgerald Downgrades Alector to Neutral From Overweight	MT
25-10-22	Mizuho Downgrades Alector to Neutral From Outperform, Cuts Price Target to $1.50 From $3.50	MT
25-07-28	Alector Shares Rise After Mizuho Upgrade	MT
25-07-28	Mizuho Upgrades Alector to Outperform From Neutral, Raises Price Target to $3.50 From $2.50	MT
24-12-17	Mizuho Downgrades Alector to Neutral From Outperform, Cuts Price Target to $2.50 From $9	MT
24-12-16	Stifel Downgrades Alector to Hold From Buy, Adjusts Price Target to $4 From $15	MT
24-12-04	BofA Securities Downgrades Alector to Underperform	MT
23-12-14	Stifel Upgrades Alector to Buy From Hold, Adjusts Price Target to $15 From $8	MT
23-12-12	Deutsche Bank Initiates Coverage on Alector With Buy Rating, $12 Price Target	MT
23-11-16	Mizuho Securities Trims Price Target on Alector to $9 From $10, Keeps Buy Rating	MT
23-09-22	Cantor Fitzgerald Starts Alector at Overweight With $13 Price Target	MT
23-08-11	Mizuho Cuts Price Target on Alector to $10 From $12, Keeps Buy Rating	MT
23-08-08	Stifel Adjusts Price Target on Alector to $8 From $10, Maintains Hold Rating	MT
23-05-05	Barclays Adjusts Price Target on Alector to $12 From $14, Maintains Overweight Rating	MT
23-03-03	Morgan Stanley Adjusts Price Target on Alector to $10 From $11, Maintains Equal-Weight Rating	MT
23-03-02	BTIG Adjusts Price Target on Alector to $16 From $54, Keeps Buy Rating	MT
23-03-02	Mizuho Adjusts Price Target on Alector to $12 From $15, Keeps Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALECTOR, INC.					+61.46%
	WUXI APPTEC CO., LTD.					+15.19%
	ARGENX SE					+23.91%
	WUXI BIOLOGICS (CAYMAN) INC.					+12.16%
	INSMED INCORPORATED					+63.75%
	BIONTECH SE					+18.06%
	GENMAB A/S					+1.55%
	PHARMAESSENTIA CORPORATION					+20.98%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+32.98%
	EXELIXIS, INC.					-7.36%
	Average					+24.27%
	Weighted average by Cap.					+20.81%